ARTICLE | Clinical News
PMPA nucleotide analog, oral form: Phase I and II Update
May 19, 1997 7:00 AM UTC
GILD began a Phase I/II study to assess safety, pharmacokinetics, tolerability and antiviral activity of oral PMPA. The study is a double-blind, placebo-controlled, dose-escalating trial in HIV-infected patients with CD4 cell counts ?200 cells/mm3 and HIV RNA ?10,000 copies/ml. Patients will receive placebo or one of several dose levels of PMPA. ...